Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.07.24.740669

Transcriptome Profiling Identifies a Natural Antisense Transcript of IRF4 Associated with EBV Latency

Abstract

Epstein-Barr virus (EBV) establishes distinct latency programs that drive B-cell transformation through coordinated viral and host gene regulation. However, the contribution of host long noncoding RNAs (lncRNAs) to EBV-mediated pathogenesis remains poorly understood. Here, we performed transcriptome-wide lncRNA profiling comparing Type I and Type III EBV latency and identified differentially expressed host lncRNAs, among which we characterized a previously unannotated natural antisense transcript (NAT) of IRF4, designated IRF4-AS1. IRF4-AS1 is markedly upregulated in Type III latency and positively correlates with IRF4 expression across EBV-transformed lymphoblastoid cell lines (LCLs) established from diverse clinical backgrounds. Functional studies indicate a context-dependent positive regulatory relationship between IRF4-AS1 and IRF4. While overexpression of IRF4-AS1 increased IRF4 expression and IRF4 overexpression increased IRF4-AS1 levels, loss-of-function analyses suggest that this relationship is modulated by additional regulatory inputs in established transformed cells. In contrast to IRF4, IRF4-AS1 transcription is not regulated by the LMP1- NF{kappa}B signaling, indicating that the two transcripts are regulated through partially distinct mechanisms. In addition, we identified MIR3142HG as a highly induced latency-associated lncRNA and found that its embedded miRNAs, miR-146a and miR-3142, exhibited divergent expression patterns, suggesting differential post-transcriptional regulation. Together, these findings identify IRF4-AS1 as a NAT lncRNA for IRF4 and reveal extensive remodeling of host lncRNA networks during EBV latency, providing a foundation for future studies of lncRNA- mediated host-virus interactions in EBV pathogenesis. ImportanceEBV drives B-cell transformation through extensive reprogramming of host transcriptional networks, yet the contribution of host long noncoding RNAs (lncRNAs) to this process remains poorly defined. Transcriptome-wide lncRNA profiling, together with functional analysis, identified IRF4-AS1 as a previously unannotated natural antisense transcript of IRF4. IRF4- AS1 is upregulated in Type III latency and positively correlates with IRF4 expression across EBV-transformed cells. Together, this study provides a foundation for future mechanistic studies of lncRNA-mediated host-virus interactions in EBV pathogenesis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wang, L., Hensley, C. R., Jahan, R., Sarpong, G. M., Anderson, A. G., Moorman, J. P., Yao, Z. Q., Ning, S.. 2026-07-26. Transcriptome Profiling Identifies a Natural Antisense Transcript of IRF4 Associated with EBV Latency. https://doi.org/10.64898/2026.07.24.740669

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

pTRIP, a novel integration plasmid for Listeria monocytogenes

In the past decades, several tools to genetically modify the human pathogen Listeria monocytogenes were developed. Here, we constructed a new integrative plasmid system for L. monocytogenes named pTRIP, for treB insertion plasmid. pTRIP is a vector which stably integrates into the treB locus of the wild type EGD-e. This locus encodes the sole trehalose-specific EIIB and EIIC component of a phosphotransferase system. Successful integration leads to the disruption of treB and thus, to an inability of the resulting L. monocytogenes strains to grow on trehalose as sole carbon source. Due to integration through double homologous recombination, it is the first integrative system which does not require antibiotic selection pressure. To assess functionality of the pTRIP system, prfA and its native promoter region were integrated into the treB locus of a {Delta}prfA strain. Complementation was confirmed in 78% of the isolated clones, indicating successful integration of prfA into the treB locus. We further constructed derivatives of pTRIP harboring the constitutive Pp60 (pTRIP1) and the inducible Prha (pTRIP2) promoter to further expand application possibilities. Microscopic analyses confirmed the functionality of both promoter constructs and showed dose-dependent induction for Prha. pTRIP is an efficient tool for stable gene expression as well as functional studies and expands genetic modification possibilities for L. monocytogenes.

microbiology↗

A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides

Peptide-based fusion inhibitors are promising pharmaceuticals in the fight against enveloped viruses relying on membrane fusion for host infection. However, peptide therapeutic applications have long been hindered by their poor stability in vivo. Here, we discovered that peptide inhibitors with the wildtype sequence of the heptad repeat 2 (HR2) domain of the SARS-CoV-2 spike protein are efficiently cleaved by Transmembrane Protease, Serine 2 (TMPRSS2), a key protease involved in the SARS-CoV-2 virus-cell fusion pathway. We then identified the corresponding cleavage sites and designed three protease-resistant peptides using ranking based on deep mutational scanning and natural occurrence. The three candidates all exhibit inhibitory activity in a cell-cell fusion assay. A high-resolution cryo-EM structure of the top candidate, HR2-NHN, bound to its HR1 target reveals the molecular basis for its potent activity. The top candidate of the cell-based screening assay significantly improved efficacy relative to the wildtype peptide when administered 12 h before infection in both an authentic virus-cell infection assay and a mouse assay. More broadly, our results suggest that the design strategies for protease-resistant peptides could be applied to a broad spectrum of other enveloped viruses and pave the way for the development of safe, prophylactic antivirals that can be administered before exposure.

microbiology↗

Host soluble inositol phosphate signaling promotes coronavirus replication

Coronaviruses rely extensively on host pathways for replication, making host-directed therapies an attractive strategy for broad-spectrum antivirals with reduced risk of viral resistance. Here we identify the host soluble inositol phosphate pathway as a previously unrecognized dependency for coronavirus infection. Genetic or pharmacologic inhibition of several kinases in this pathway markedly suppresses replication of both alpha- and betacoronaviruses, while increasing pathway activity promotes viral replication. We developed UNC7844, a potent multi-target inhibitor of these kinases, which reduces coronavirus replication by more than four orders of magnitude in cultured cells and suppresses coronavirus infection in mice. Mechanistically, UNC7844 suppresses inositol (pyro)phosphates production, disrupts phosphoinositide homeostasis, and impairs late endosomal dynamics, blocking early post-entry steps required for viral genome release and replication. Together, our findings establish the soluble inositol (pyro)phosphate pathway as an important regulator of coronavirus infection and highlight its inhibition as a promising host-directed antiviral strategy.

microbiology↗